306 related articles for article (PubMed ID: 16519257)
1. Management of visceral leishmaniasis: Indian perspective.
Agrawal S; Rai M; Sundar S
J Postgrad Med; 2005; 51 Suppl 1():S53-7. PubMed ID: 16519257
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
[TBL] [Abstract][Full Text] [Related]
3. Oral miltefosine for the treatment of Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Bhattacharya SK; Rai M
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S26-33. PubMed ID: 16730038
[TBL] [Abstract][Full Text] [Related]
4. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
[TBL] [Abstract][Full Text] [Related]
5. Visceral leishmaniasis - current therapeutic modalities.
Sundar S; Chatterjee M
Indian J Med Res; 2006 Mar; 123(3):345-52. PubMed ID: 16778315
[TBL] [Abstract][Full Text] [Related]
6. Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis.
Sundar S; Jha TK; Sindermann H; Junge K; Bachmann P; Berman J
Pediatr Infect Dis J; 2003 May; 22(5):434-8. PubMed ID: 12792385
[TBL] [Abstract][Full Text] [Related]
7. Oral miltefosine for Indian visceral leishmaniasis.
Sundar S; Jha TK; Thakur CP; Engel J; Sindermann H; Fischer C; Junge K; Bryceson A; Berman J
N Engl J Med; 2002 Nov; 347(22):1739-46. PubMed ID: 12456849
[TBL] [Abstract][Full Text] [Related]
8. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
9. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
[TBL] [Abstract][Full Text] [Related]
10. [Visceral leishmaniasis: clinical sensitivity and resistance to various therapeutic agents].
Janvier F; Morillon M; Olliaro P
Med Trop (Mars); 2008 Feb; 68(1):89-101. PubMed ID: 18478781
[TBL] [Abstract][Full Text] [Related]
11. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis F; Sundar S; Hailu A; Ghalib H; Rijal S; Peeling RW; Alvar J; Boelaert M
Nat Rev Microbiol; 2007 Nov; 5(11):873-82. PubMed ID: 17938629
[TBL] [Abstract][Full Text] [Related]
12. Visceral leishmaniasis (kala-azar): challenges ahead.
Singh RK; Pandey HP; Sundar S
Indian J Med Res; 2006 Mar; 123(3):331-44. PubMed ID: 16778314
[TBL] [Abstract][Full Text] [Related]
13. Injectable paromomycin for Visceral leishmaniasis in India.
Sundar S; Jha TK; Thakur CP; Sinha PK; Bhattacharya SK
N Engl J Med; 2007 Jun; 356(25):2571-81. PubMed ID: 17582067
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in Indian visceral leishmaniasis.
Sundar S
Trop Med Int Health; 2001 Nov; 6(11):849-54. PubMed ID: 11703838
[TBL] [Abstract][Full Text] [Related]
15. K39 strip test--easy, reliable and cost-effective field diagnosis for visceral leishmaniasis in India.
Goswami RP; Bairagi B; Kundu PK
J Assoc Physicians India; 2003 Aug; 51():759-61. PubMed ID: 14651134
[TBL] [Abstract][Full Text] [Related]
16. Visceral leishmaniasis (kala-azar)--the Bihar (India) perspective.
Sinha PK; Ranjan A; Singh VP; Das VN; Pandey K; Kumar N; Verma N; Lal CS; Sur D; Manna B; Bhattacharya SK
J Infect; 2006 Jul; 53(1):60-4. PubMed ID: 16269185
[TBL] [Abstract][Full Text] [Related]
17. Treatment of visceral leishmaniasis in 2004.
Murray HW
Am J Trop Med Hyg; 2004 Dec; 71(6):787-94. PubMed ID: 15642973
[TBL] [Abstract][Full Text] [Related]
18. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
[TBL] [Abstract][Full Text] [Related]
19. Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India.
Thakur CP; Narayan S; Ranjan A
Indian J Med Res; 2004 Sep; 120(3):166-72. PubMed ID: 15489554
[TBL] [Abstract][Full Text] [Related]
20. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
Ritmeijer K; Dejenie A; Assefa Y; Hundie TB; Mesure J; Boots G; den Boer M; Davidson RN
Clin Infect Dis; 2006 Aug; 43(3):357-64. PubMed ID: 16804852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
